NAMI Highlights Concerns With ICER's Review of TRD
(6/6, National Pharmaceutical Council: E.V.I.dently Today) comments “...Patient organizations, including the National Alliance on Mental Illness, the nation's largest grassroots mental health organization, have weighed in during ICER's assessment process to ensure that the concerns of people living with [treatment-resistant depression] are considered. NAMI Director of Legislative Advocacy Andrew Sperling, who has participated in previous ICER assessments, most recently for one on tardive dyskinesia, shared NAMI's experience with this latest ICER review and how his organization's previous efforts influenced its approach.” Full
A Broken System – Making Drug Decisions without Real-World Data
(6/6, William Kirsh, PharmExec) reports “...‘Real-world evidence demands real-world data. Period. This data provides the only path for a clinician to practice evidentiary medicine that is truly incontrovertible. The proliferation of exorbitantly expensive drugs necessitates a new way of selecting the right medications for the right conditions based on actual patient outcomes,’ says Travis Leonardi, CEO and Founder of healthcare analytics and technology company Sentry Data Systems. ‘Hospital leaders must rely on a drug selection process rooted in evidence and based on real-world data in order to thrive.’” Full
Payer Access Special Feature: The Values in Value Frameworks
(6/6, Christiane Truelove, PharmaLive) reports “...‘I don't think anybody disagrees that it is going to evolve and we'll live in a world where HTAs work very similarly to those outside of the United States but it's not quite there yet,’ [Adrian Garcia, senior VP, head of payer and integrated health strategy at GSW,] says. ‘The concern that many manufacturers have is that if they start to engage organizations like ICER proactively or even reactively, it almost gives them credibility.’ Still, according to Garcia, ‘there is plenty of engagement, but most of it is behind closed doors, through back channels, trying to stave off the influence that organizations like ICER will have.’” Full
Assessing Value Top of Mind at ISPOR 2019
(6/5, Samantha Dougherty, PhRMA: The Catalyst) comments “As we move toward a value-driven health care system, the focus should be on outcomes that matter most to patients, such as how medicines make patients feel, whether they can return to work or how their quality of life has improved. Advancing research and methods related to value assessment is an important step toward that goal. At ISPOR 2019, a conference about health economics and outcomes research and its use in health care decisions, thought leaders discussed how to better measure value in health care.” Full
Treatment Patterns, Glycemic Control & Bodyweight with Canagliflozin 300 mg Versus GLP1RAs in Type II Diabetes Patients
Craig I Coleman, et al.
June 6, 2019, Journal of Comparative Effectiveness Research
Journal of Comparative Effectiveness Research
Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Spain
Schlueter M, et al.
June 6, 2019, ClinicoEconomics and Outcomes Research
Improving Quality Measure Maintenance: Navigating the Complexities of Evolving Evidence
Thomas B. Valuck, MD, JD, et al.
June 6, 2019, The American Journal of Managed Care